MRA will introduce a new state of the art sterility suite in 3rd quarter 2016. This cleanroom and equipment will provide primary engineering control for microbial contamination risk reduction enabling a more robust environment for USP <71> Sterility Testing for parenterals and compounding IVs.
The sterility suite will be further enhanced with isolator technology to achieve closed system status eliminating outside microbial contamination from facility, equipment and/or personnel insuring the veracity of product sterility and ultimately patient care.
To advance MRA’s quality and compliance commitment to our clients, we will also equip our new cleanroom with hazardous drug capture technology, thereby supporting chemistry of chemotherapy drug and compliance to USP compendial sections <71>, <797> and <800>.
These new services will strengthen our relationships with clients in both cGMP and DQSA regulated business environments.